IMMU will present the 132 data in Pancreatic cancer at a meeting on May 18. If the data were any good the company would wait another 3 weeks before announcing a stock offering.
I made money on MEDX and I am long on IMMU. I hope the 132 data are good. By the way, BMY would be the perfect buyer for IMMU. They have lots of antibodies from MEDX and they would be a good fit for IMMU's dock and lock technology.
I bought today @ 3.24, and I feel pretty damn good about it. The company now has needed working capital, and is way oversold. If the market cooperates, this will be back over 4 in a matter of 2 to 3 weeks. IMHO.
Very likely IMMU's pps will rise, but your timetable may be a little off. Terms of offering are 30 days at $3.35. In the larger scheme the big event is the topline emab results supposedly due in 1Q 2015. If this P3 trial fails, IMMU's future looks bleak indeed. If successful, the stock will soar.